BMS also has its wholly owned dual-immunotherapy regimen, a combination of Opdivo and CTLA-4 agent Yervoy, which has been marketed since April 2018 in kidney cancer and has longer-term survival data. But that pairing is approved specifically for intermediate- and high-risk patients, while both Keytruda-Inlyta and Opdivo-Cabometyx have delivered benefits for patients regardless of their disease risk profile. Right now, Graybosch expects doctors to continue to prefer BMS' dual-immunotherapy regimen, "especially for patients with slower growing, smaller tumors." As for the two combos of PD-1 and TKI, it could be anybody's game, as physicians will choose their favorite regimen, she said.